These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 34669740)

  • 1. Correction: A randomized, open-label, parallel, multi-center Phase IV study to compare the efficacy and safety of atorvastatin 10 and 20 mg in high-risk Asian patients with hypercholesterolemia.
    Kim JB; Song WH; Park JS; Youn TJ; Park YH; Kim SJ; Ahn SG; Doh JH; Cho YH; Kim JW
    PLoS One; 2021; 16(10):e0259072. PubMed ID: 34669740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Efficacy and Tolerability of Ezetimibe in Combination With Atorvastatin in Japanese Patients With Hypercholesterolemia-Ezetimibe Phase IV Randomized Controlled Trial in Patients With Hypercholesterolemia.
    Teramoto T; Sawada T; Iwamoto K; Daida H
    Curr Ther Res Clin Exp; 2012 Feb; 73(1-2):16-40. PubMed ID: 24653510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE; Feely J; Sigurdsson EL;
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.
    Stein E; Stender S; Mata P; Sager P; Ponsonnet D; Melani L; Lipka L; Suresh R; Maccubbin D; Veltri E;
    Am Heart J; 2004 Sep; 148(3):447-55. PubMed ID: 15389231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomised study comparing the efficacy and safety of rosuvastatin with atorvastatin for achieving lipid goals in clinical practice in Asian patients at high risk of cardiovascular disease (DISCOVERY-Asia study).
    Zhu JR; Tomlinson B; Ro YM; Sim KH; Lee YT; Sriratanasathavorn C
    Curr Med Res Opin; 2007 Dec; 23(12):3055-68. PubMed ID: 18196620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative efficacy and safety of low-dose pitavastatin versus atorvastatin in patients with hypercholesterolemia.
    Sansanayudh N; Wongwiwatthananukit S; Putwai P; Dhumma-Upakorn R
    Ann Pharmacother; 2010 Mar; 44(3):415-23. PubMed ID: 20179259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia.
    Lee SH; Chung N; Kwan J; Kim DI; Kim WH; Kim CJ; Kim HS; Park SH; Seo HS; Shin DG; Shin YW; Shim WJ; Ahn TH; Ho Yun K; Yoon MH; Cha KS; Choi SW; Han SW; Hyon MS
    Clin Ther; 2007 Nov; 29(11):2365-73. PubMed ID: 18158077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pitavastatin - results from phase III & IV.
    Betteridge J
    Atheroscler Suppl; 2010 Dec; 11(3):8-14. PubMed ID: 21193153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of low-dose atorvastatin and rosuvastatin on plasma lipid profiles: a long-term, randomized, open-label study in patients with primary hypercholesterolemia.
    Mazza F; Stefanutti C; Di Giacomo S; Vivenzio A; Fraone N; Mazzarella B; Bucci A
    Am J Cardiovasc Drugs; 2008; 8(4):265-70. PubMed ID: 18690760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Superior benefit of aggressive lipid-lowering therapy for high- risk patients using statins: the SUBARU study--more hypercholesterolemic patients achieve Japan Atherosclerosis Society LDL-C goals with rosuvastatin therapy than with atorvastatin therapy.
    Kurabayashi M; Yamazaki T;
    J Atheroscler Thromb; 2008 Dec; 15(6):314-23. PubMed ID: 19060425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing the efficacy and safety of atorvastatin and simvastatin in Asians with elevated low-density lipoprotein-cholesterol--a multinational, multicenter, double-blind study.
    Wu CC; Sy R; Tanphaichitr V; Hin AT; Suyono S; Lee YT
    J Formos Med Assoc; 2002 Jul; 101(7):478-87. PubMed ID: 12353340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): the PATROL trial.
    Saku K; Zhang B; Noda K;
    Circ J; 2011; 75(6):1493-505. PubMed ID: 21498906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correction: Providing open-label placebos remotely-A randomized controlled trial in allergic rhinitis.
    Kube T; Hofmann VE; Glombiewski JA; Kirsch I
    PLoS One; 2021; 16(6):e0252850. PubMed ID: 34077482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in patients with primary hypercholesterolemia: results from the ECLIPSE study.
    Faergeman O; Hill L; Windler E; Wiklund O; Asmar R; Duffield E; Sosef F;
    Cardiology; 2008; 111(4):219-28. PubMed ID: 18434729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correction: Infliximab for pediatric patients with Crohn's disease: A Phase 3, open-label, uncontrolled, multicenter trial in Japan.
    Tajiri H; Motoya S; Kinjo F; Maemoto A; Matsumoto T; Sato N; Yamada H; Nagano M; Susuta Y; Ozaki K; Kondo K; Hibi T
    PLoS One; 2022; 17(4):e0261932. PubMed ID: 35439252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correction: A multi-center randomized prospective study on the treatment of infant bronchiolitis with interferon α1b nebulization.
    Chen L; Shi M; Deng Q; Liu W; Li Q; Ye P; Yu X; Zhang B; Xu Y; Li X; Yang Y; Li M; Yan Y; Xu Z; Yu J; Xiang L; Tang X; Wan G; Cai Q; Wang L; Hu B; Xie L; Li G; Xie L; Liu X; Liu C; Li L; Chen L; Jiang X; Huang Y; Wang S; Guo J; Shi Y; Li L; Wang X; Zhao Z; Li Y; Liu Y; Fu Q; Zeng Y; Zou Y; Liu D; Wan D; Ai T; Liu H
    PLoS One; 2020; 15(4):e0231911. PubMed ID: 32275690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complementary low-density lipoprotein-cholesterol lowering and pharmacokinetics of adding bempedoic acid (ETC-1002) to high-dose atorvastatin background therapy in hypercholesterolemic patients: A randomized placebo-controlled trial.
    Lalwani ND; Hanselman JC; MacDougall DE; Sterling LR; Cramer CT
    J Clin Lipidol; 2019; 13(4):568-579. PubMed ID: 31202641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerability of two different formulations of atorvastatin in Korean patients with hypercholesterolemia: a multicenter, prospective, randomized clinical trial.
    Lee JH; Kim SH; Choi DJ; Tahk SJ; Yoon JH; Choi SW; Hong TJ; Kim HS
    Drug Des Devel Ther; 2017; 11():2277-2285. PubMed ID: 28814835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of a new cholesterol synthesis inhibitor, atorvastatin, in comparison with simvastatin and pravastatin, in subjects with hypercholesterolemia.
    Wolffenbuttel BH; Mahla G; Muller D; Pentrup A; Black DM
    Neth J Med; 1998 Apr; 52(4):131-7. PubMed ID: 9646621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.